迪哲医药(688192) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for the third quarter reached ¥231,299,714.08, representing a year-on-year increase of 71.46%[3] - The total profit for the period was a loss of ¥203,910,752.21, with a cumulative loss of ¥582,901,080.21 for the year to date[3] - The basic earnings per share for the current period was -¥0.44, compared to -¥1.32 for the year to date[3] - The net profit for the first three quarters of 2025 was -582,953,152.35 RMB, compared to -649,647,448.06 RMB in the same period of 2024, showing an improvement[25] - Basic and diluted earnings per share for the first three quarters of 2025 were both -1.32 RMB, slightly better than -1.35 RMB in 2024[25] - The total comprehensive income attributable to the parent company's owners was -579,947,780.97 RMB in 2025, compared to -558,460,529.94 RMB in 2024[25] Research and Development - Research and development expenses totaled ¥235,968,603.38, accounting for 102.02% of revenue in the current period, a decrease of 35.09 percentage points[4] - The company plans to maintain stable funding for ongoing clinical research and development of its products[9] - The company is actively expanding its research and development efforts, particularly in the field of T-cell lymphoma treatment, as evidenced by multiple studies on its product, 高瑞哲®[16] - Research and development expenses increased to 644,235,609.66 RMB in 2025 from 567,728,545.76 RMB in 2024, reflecting a growth of approximately 13.5%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,955,346,622.51, an increase of 71.95% compared to the end of the previous year[4] - The equity attributable to shareholders of the listed company increased to ¥1,440,437,716.45, reflecting a significant rise of 643.43% year-on-year[4] - As of September 30, 2025, the company's total assets amounted to RMB 2,955,346,622.51, a significant increase from RMB 1,718,737,884.05 at the end of 2024[19][21] - The company’s total liabilities as of September 30, 2025, were RMB 1,511,613,180.21, slightly down from RMB 1,518,680,986.42 at the end of 2024[21] Cash Flow - The net cash flow from operating activities was -¥159,387,479.24 for the current period, with a cumulative cash flow of -¥424,056,847.98 for the year[3] - Operating cash flow for the first three quarters of 2025 was -424,056,847.98 RMB, slightly better than -463,308,340.42 RMB in 2024[28] - The company reported a significant increase in cash inflow from investment activities, totaling 7,282,910,041.68 RMB in 2025 compared to 2,709,870,267.04 RMB in 2024[28] - The net cash flow from financing activities was 1,640,908,417.60 RMB in 2025, compared to 606,803,240.41 RMB in 2024, indicating a substantial increase[29] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,806[11] - The largest shareholder, Advanced Manufacturing Industry Investment Fund, holds 108,923,023 shares, representing 23.71% of total shares[11] - AstraZeneca AB also holds 108,923,023 shares, accounting for 23.71%[11] - The company’s stockholders include Jiangsu Wuxi Dize Enterprise Management Partnership, holding 57,451,788 shares, or 12.51%[11] - The company’s stockholders also include Industrial Bank Co., Ltd. - Yongying Pharmaceutical Innovation Mixed Fund, holding 5,910,918 shares, or 1.29%[11] Product Development and Approvals - The company received FDA accelerated approval for ZEGFROVY® on July 2025, making it the first and only EGFR Exon20ins NSCLC innovative drug approved in the U.S.[13] - The company presented 11 new research results in the NSCLC field at the 2025 WCLC, demonstrating good efficacy and safety for ZEGFROVY® across various treatment stages[14] - Birelentinib (DZD8586) received FDA Fast Track Designation in August 2025 for treatment of relapsed/refractory CLL/SLL patients[15] - The company has initiated an international multi-center Phase III clinical study for birelentinib targeting relapsed/refractory CLL/SLL[15] - The company’s research on high瑞哲® (Golitinib) in combination with anti-PD-1 monoclonal antibodies is ongoing, providing important evidence for its clinical application in NSCLC[14] Operating Costs - Total operating revenue of RMB 586,301,134.90 for the first three quarters of 2025, a significant increase from RMB 338,451,000.00 in the same period of 2024, representing a growth of approximately 73.4%[23] - Total operating costs for the first three quarters of 2025 were RMB 1,234,483,936.24, compared to RMB 1,031,763,876.35 in the first three quarters of 2024, indicating an increase of about 19.6%[23] - The company incurred financial expenses of 22,699,804.01 RMB in 2025, up from 15,863,566.73 RMB in 2024, representing a rise of about 43.3%[24] - Sales revenue from goods and services received cash of 559,618,110.76 RMB in 2025, compared to 351,202,757.00 RMB in 2024, marking a growth of approximately 59.4%[28]